Who we are

Owen Mumford specialises in integrated design and build services from a broad range of self-injection platform devices for the pharmaceutical industry.

From the first automatic lancing device to our patented self-injection devices, with Owen Mumford you have access to unrivalled experience in designing, developing and delivering solutions to help you make adherence easier for patients.


With more than 65 years’ experience, your device is in trusted hands with Owen Mumford.

From day one, we will guide you throughout the development process; at every step, you will benefit from professional and supportive project management, processes, industrialisation and production for a smooth development and launch.

The springless, passive safety device for pre-filled syringes

Fully designed, developed and ready for commercial supply

Comfort

Large, ergonomic plunger head and a smooth, integrated finger flange, resulting in an integrated look and feel.

Secure plunger

Plunger cannot detach when removing the RNS.

Reduced risk

No compromise to sterility in assembly – plunger does not touch the bung.

User confidence

Syringe barrel is unobscured, allowing the user to check the contents of the syringe, and to confirm the full dose has been delivered.

Reliability

Prevention of occidental activation e.g. in transit.

Simple 2-step final sembly

Final assembly process is simple and outside of the sterile filling area.

Cost effective

Designed to work with standard, pre-filled syringes which means no change to existing primary container and minimises training costs.

Passive safety

Passive needle retraction means that the device is safe as soon as the plunger is fully depressed

Self-Injection Device Solutions 

Ensuring that patients are willing and able to inject their medication is key to their well-being. As pioneers in self-injection technologies, our experience enables us to effectively work with you to find the right drug delivery solution.


Please visit: omdevicesolutions.com

Go to article: Home | The power of patientsGo to article: Scandinavian Health Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: CapsugelGo to article: Capsugel Company Insight Go to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: Molnar Company InsightGo to article: Molnar-InstituteGo to article: A costly oversight: the ongoing impact of the valsartan recallGo to article: Novo Nordisk Company InsightGo to article: Novo NordiskGo to article: Where is the UK’s supply of Migraleve?Go to article: Dupont PharmaceuticalsGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Charting the life and times of the EMA as it leaves LondonGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: CBD: the myth, the magic and the real deal drugsGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: How do cancer cells communicate and can it help us catch them?Go to article: HOF SonderanlagenbauGo to article: HOF Sonderanlagenbau Company Insight Go to article: Buyers’ clubs: the first step toward universal UK access to Orkambi?Go to article: SterigenicsGo to article: Owen MumfordGo to article: Are we nearing the end of animal testing in pharma?Go to article: Zenatek Go to article: Barc Lab Go to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Abiogen PharmaGo to article: MimotopesGo to article: Next issue